Plain-English translation of NCT07559201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging technology called ACP3 PET/CT that may help doctors better detect prostate cancer and spot whether cancer has returned after treatment. You would receive an injection of a radioactive tracer and then undergo a PET/CT scan, which takes pictures to show where cancer cells are located. The scan results will be compared to standard imaging methods to see how well this new approach works.
Current imaging methods for detecting prostate cancer and cancer recurrence have limitations. This trial exists to see whether the new ACP3 scan is better at finding cancer cells and helping doctors make treatment decisions for patients with prostate cancer.
You likely qualify if…
You likely don't qualify if…
You would visit the research center for imaging scans. First, you'll receive an injection of a radioactive tracer through an IV, and then you'll lie still while the PET/CT scanner takes detailed pictures of your body. You'll also have a standard imaging scan (the current method) done around the same time. The whole process typically takes a few hours, and you'll need to complete both scans to participate fully in the trial.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Sponsor
Guilin Medical University, China
Enrollment target
~100 participants
Started
January 2026
Primary completion
December 2029
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingyu Mu, PhD
Guilin Medical University, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.